Boulevard Bio raises $65M
Boulevard Bio announced a Seed round of $65M on 12 August 2026. The company operates in HealthTech and is based in United States. It was founded by Mahesh Karande, CEO.
Founder
Mahesh Karande
CEO, Boulevard Bio
Outreach angles
- -CEO Mahesh Karande launched Boulevard Bio out of stealth alongside co-founders Georg Schett, a B cell researcher, and Frank Nestle, a Deerfield partner and 3DC CEO.
- -Karande has emphasized the company's focus on patient-centric science that can make a difference in patients' lives.
- -The $65 million round, led by Deerfield Management, funds Boulevard Bio's lead antibody candidate for IgA nephropathy alongside two other autoimmune disease programs.
Signals
SeedHealthcareDeep TechSecond-Time FounderRegulated Industry
Round details
Company: Boulevard Bio
Domain: boulevardbio.com
Amount: $65M
Stage: Seed
Industry: HealthTech
Country: United States
Announced: 12 August 2026
Other HealthTech raises
Recently funded in United States